ATRS - Antares Pharma trades higher on revenue guidance for FY 2021

Antares Pharma ([[ATRS]] +2.5%) expects revenue for FY 2021 to be in a range of $175-$200M, which assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic.The Co. also updated its guidance for FY 2020 and expects revenue to be in a range of $145-$150M from $135-$155M. "Our expectations for 19-36% Y/Y revenue growth in 2021, based on the mid-point of the 2020 guidance, also assumes a range of revenue scenarios for the potential approval and launch of Forteo by our partner Teva in the U.S.” said Robert F. Apple, President and CEO.

For further details see:

Antares Pharma trades higher on revenue guidance for FY 2021